Stem Cell Therapy for Pediatric Type 1 Diabetes: Current Evidence, Challenges, and Future Directions

Abstract

Type 1 diabetes mellitus (T1DM) in children poses significant lifelong challenges. Current insulin-based therapies effectively manage glycemic control but do not offer a cure. Stem cell therapy has been investigated as a promising treatment for T1DM. This review consolidates current evidence regarding stem cell therapies for managing T1DM in children, focusing on stem cell sources, mechanisms of action, clinical outcomes, and associated challenges. Methods: A structured narrative review was conducted. Relevant studies, clinical trials, and reports were sourced from PubMed and other scientific databases. Priority was given to pediatric studies, mixed-population studies with extractable pediatric data, and clinical trials assessing efficacy, safety, and feasibility. Results: Evidence suggests that various stem cell types including hematopoietic stem cells (HSCs), mesenchymal stem cells (MSCs), and pluripotent-derived β-like cells have the potential to enhance C-peptide levels, reduce the need for exogenous insulin, and modulate autoimmunity. In one study of autologous HSCs transplantation, 59% of participants achieved insulin independence within 6 months, while 32% remained insulin independent at the last follow-up. HbA1c decreased accompanied by an increase in C-peptide. However, these effects have largely been demonstrated in small studies involving adolescents, young adults, or mixed-age populations and have been achieved using immunosuppressive regimens associated with toxicity, whereas MSCs based studies generally demonstrate more improvements in β-cell function and insulin requirements. These findings must be interpreted cautiously because pediatric-specific studies are still limited, and outcomes vary considerably depending on the disease stage, cell type, delivery method, and immunosuppression protocols. Conclusion: Stem cell therapy represents a promising yet still experimental approach for pediatric T1DM. Well-designed pediatric clinical trials are essential to establish efficacy and ensure safety before these therapies can be widely implemented in clinical practice. Future pediatric trials should consequently prioritize approaches that achieve immune modulation or β-cell replacement without myeloablative or intensive immunosuppressive conditioning.